- Swine Vaccine
- Cattle Vaccine
- Companion Animal Vaccines
The swine, ruminant and companion animal vaccines market was valued at USD 4,656.6 million in 2022, with a strong CAGR of 6.1 percent from 2023 to 2029. The swine, ruminant, and companion animal vaccines market is expected to experience steady growth due to increased pet ownership in developed countries and a rise in the number of cattle & poultry in developing countries. Furthermore, the rise in investment in research and development of vaccines, which inhibit the growth of antibiotic-resistant organisms, boosts the growth of the swine, ruminant, and companion animal vaccines market. Productivity in livestock is severely impacted by the presence of a few bacterial, viral, and protozoan borne diseases. Timely vaccination prevents the risk of infection and affects a farmers income through livestock rearing. Furthermore, the rate of developing infectious diseases continues to rise, necessitating the rapid deployment of new vaccinations. For effective disease eradication, it is critical to identify such diseases and vaccinate animals regularly. Because of advancements in technology and medicine and our comprehensive knowledge of immunology, molecular biology, microbiology, and biochemistry, among other basic science fields, new vaccine manufacturing methods have emerged, providing several chances to key market players. In the swine, ruminant, and companion animal vaccines market size, the attenuated vaccines segment dominated the product type segment with the largest share. By stimulating a wide spectrum of immune responses, attenuated vaccines can deliver better immunity than conventional vaccines. Furthermore, it helps to lessen the need for booster vaccinations that can be given orally and generates long-lasting and fast immunity, all of which contribute to the growth of the swine, ruminant, and companion animal vaccines market.
Swine, Ruminant and Companion Animals Vaccines Market Key Developments:
In August 2021, Zoetis Inc. announced it has entered into an agreement to acquire Jurox, a privately held animal health company, which develops, manufactures, and markets a wide range of veterinary medicines for treating companion animals and livestock. Juroxs operations are based in Australia, with additional regional offices and subsidiaries in New Zealand, U.S., Canada, and the UK. Financial terms of the transaction are not being disclosed. In August 2021, as part of Sanofis endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion
Swine Ruminant And Companion Animals Vaccines Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
6.1%
Largest Market
North America
Fastest Growing Market
Europe
Swine, Ruminant and Companion Animals Vaccines Market Dynamics
The rising prevalence of zoonotic illnesses could negatively influence human health, driving up demand for swine, ruminant, and companion animal vaccines. Human and animal health are increasingly threatened by emerging and exotic animal illnesses, undermining food security. Furthermore, the lack of animal health awareness and the potential for adverse effects of veterinary vaccinations on human and other animal health limit the market's growth.
North-America Got Significant Share
Swine, Ruminant and Companion Animals Vaccines Market Regional Analysis
In 2022, North America led the market and held a bigger share. The high incidence of livestock and zoonotic illnesses, which result in large-scale animal mortality, can be blamed for this enormous share. Furthermore, due to the large number of well-established pharmaceutical companies that are continually attempting to expand their geographical reach and commercialize their vaccines, the market is expected to grow. In addition, the increased prevalence of canine illnesses, which is driving up vaccination adoption, and the growing pet population in the United States are two significant factors driving the regional market forward.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The swine, ruminant and companion animals vaccines market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Swine Ruminant And Companion Animals Vaccines Market Segmentation
By Product Type
By Disease
- Swine Disease
- Cattle Diseases
- Companion Animal Diseases
By Geography
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Frequently Asked Questions
The Swine, Ruminant and Companion Animals Vaccines Market is projected to expand at a CAGR of 6.1% during the forecast period.
The major players in the global swine, ruminant, and companion animals vaccines market are ??? Boehringer Ingelheim International GmbH., IDT Biologika GmbH, HIPRA, Ceva Sante Animale, Elanco, Arko Laboratories Ltd, Merial, Vetoquinol, Zoetis Inc., Phibro Animal Health Corporation, Merck & Co., Inc., and Virbac.
Europe is the fastest-growing region for Swine, Ruminant and Companion Animals Vaccines Market
| 1. Executive Summary |
| 2. Global Swine, Ruminant and Companion Animals Vaccines Market Introduction |
| 2.1. Global Swine, Ruminant and Companion Animals Vaccines Market Taxonomy |
| 2.2. Global Swine, Ruminant and Companion Animals Vaccines Market Definitions |
| 2.2.1. By Product |
| 2.2.2. By Disease |
| 2.2.3. By Region |
| 3. Global Swine, Ruminant and Companion Animals Vaccines Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Swine, Ruminant and Companion Animals Vaccines Market Dynamic Factors - Impact Analysis |
| 4. Global Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Swine, Ruminant and Companion Animals Vaccines Market, By Product, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Swine Vaccine |
| 5.1.1. Inactivated Vaccines |
| 5.1.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.1.3. Market Opportunity Analysis |
| 5.1.2. Live Attenuated Vaccines |
| 5.1.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.2.3. Market Opportunity Analysis |
| 5.1.3. Others |
| 5.1.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3.3. Market Opportunity Analysis |
| 5.2. Cattle Vaccine |
| 5.2.1. Toxoid |
| 5.2.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.1.3. Market Opportunity Analysis |
| 5.2.2. Recombinant |
| 5.2.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.2.3. Market Opportunity Analysis |
| 5.2.3. Inactivated |
| 5.2.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3.3. Market Opportunity Analysis |
| 5.3. Companion Animal Vaccines |
| 5.3.1. Attenuated Live Vaccine |
| 5.3.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.1.3. Market Opportunity Analysis |
| 5.3.2. Inactivated Vaccine |
| 5.3.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.2.3. Market Opportunity Analysis |
| 5.3.3. Others |
| 5.3.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3.3. Market Opportunity Analysis |
| 6. Global Swine, Ruminant and Companion Animals Vaccines Market, By Disease, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1. Swine Disease |
| 6.1.1. Diarrhea |
| 6.1.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.1.3. Market Opportunity Analysis |
| 6.1.2. Swine Influenza |
| 6.1.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.2.3. Market Opportunity Analysis |
| 6.1.3. Bordetella Rhinitis |
| 6.1.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3.3. Market Opportunity Analysis |
| 6.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 6.1.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.4.3. Market Opportunity Analysis |
| 6.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 6.1.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.5.3. Market Opportunity Analysis |
| 6.1.6. Other Diseases |
| 6.1.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.6.3. Market Opportunity Analysis |
| 6.2. Cattle Diseases |
| 6.2.1. FMD |
| 6.2.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.1.3. Market Opportunity Analysis |
| 6.2.2. Infectious Respiratory Diseases |
| 6.2.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.2.3. Market Opportunity Analysis |
| 6.2.3. Reproductive Disorders |
| 6.2.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3.3. Market Opportunity Analysis |
| 6.2.4. Others |
| 6.2.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.4.3. Market Opportunity Analysis |
| 6.3. Companion Animal Diseases |
| 6.3.1. Rabies |
| 6.3.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.1.3. Market Opportunity Analysis |
| 6.3.2. Hepatitis |
| 6.3.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.2.3. Market Opportunity Analysis |
| 6.3.3. Leukemia |
| 6.3.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3.3. Market Opportunity Analysis |
| 6.3.4. Others |
| 6.3.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.4.3. Market Opportunity Analysis |
| 7. Global Swine, Ruminant and Companion Animals Vaccines Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Region, 2023 - 2029 |
| 8. North America Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1. Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Swine Vaccine |
| 8.1.1.1. Inactivated Vaccines |
| 8.1.1.2. Live Attenuated Vaccines |
| 8.1.1.3. Others |
| 8.1.2. Cattle Vaccine |
| 8.1.2.1. Toxoid |
| 8.1.2.2. Recombinant |
| 8.1.2.3. Inactivated |
| 8.1.3. Companion Animal Vaccines |
| 8.1.3.1. Attenuated Live Vaccine |
| 8.1.3.2. Inactivated Vaccine |
| 8.1.3.3. Others |
| 8.2. Disease Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Swine Diseases |
| 8.2.1.1. Diarrhea |
| 8.2.1.2. Swine Influenza |
| 8.2.1.3. Bordetella Rhinitis |
| 8.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 8.2.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 8.2.1.6. Other Diseases |
| 8.2.2. Cattle Diseases |
| 8.2.2.1. FMD |
| 8.2.2.2. Infectious Respiratory Diseases |
| 8.2.2.3. Reproductive Disorders |
| 8.2.2.4. Others |
| 8.2.3. Companion Animal Diseases |
| 8.2.3.1. Rabies |
| 8.2.3.2. Hepatitis |
| 8.2.3.3. Leukemia |
| 8.2.3.4. Others |
| 8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. USA |
| 8.3.2. Canada |
| 8.4. North America Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Country, 2023 - 2029 |
| 8.5. North America Swine, Ruminant and Companion Animals Vaccines Market Dynamics Trends |
| 9. Europe Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1. Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Swine Vaccine |
| 9.1.1.1. Inactivated Vaccines |
| 9.1.1.2. Live Attenuated Vaccines |
| 9.1.1.3. Others |
| 9.1.2. Cattle Vaccine |
| 9.1.2.1. Toxoid |
| 9.1.2.2. Recombinant |
| 9.1.2.3. Inactivated |
| 9.1.3. Companion Animal Vaccines |
| 9.1.3.1. Attenuated Live Vaccine |
| 9.1.3.2. Inactivated Vaccine |
| 9.1.3.3. Others |
| 9.2. Disease Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Swine Diseases |
| 9.2.1.1. Diarrhea |
| 9.2.1.2. Swine Influenza |
| 9.2.1.3. Bordetella Rhinitis |
| 9.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 9.2.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 9.2.1.6. Other Diseases |
| 9.2.2. Cattle Diseases |
| 9.2.2.1. FMD |
| 9.2.2.2. Infectious Respiratory Diseases |
| 9.2.2.3. Reproductive Disorders |
| 9.2.2.4. Others |
| 9.2.3. Companion Animal Diseases |
| 9.2.3.1. Rabies |
| 9.2.3.2. Hepatitis |
| 9.2.3.3. Leukemia |
| 9.2.3.4. Others |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Spain |
| 9.3.5. Italy |
| 9.3.6. Russia |
| 9.3.7. Rest of Europe |
| 9.4. Europe Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Country, 2023 - 2029 |
| 9.5. Europe Swine, Ruminant and Companion Animals Vaccines Market Dynamics Trends |
| 10. Asia-Pacific Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1. Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Swine Vaccine |
| 10.1.1.1. Inactivated Vaccines |
| 10.1.1.2. Live Attenuated Vaccines |
| 10.1.1.3. Others |
| 10.1.2. Cattle Vaccine |
| 10.1.2.1. Toxoid |
| 10.1.2.2. Recombinant |
| 10.1.2.3. Inactivated |
| 10.1.3. Companion Animal Vaccines |
| 10.1.3.1. Attenuated Live Vaccine |
| 10.1.3.2. Inactivated Vaccine |
| 10.1.3.3. Others |
| 10.2. Disease Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Swine Diseases |
| 10.2.1.1. Diarrhea |
| 10.2.1.2. Swine Influenza |
| 10.2.1.3. Bordetella Rhinitis |
| 10.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 10.2.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 10.2.1.6. Other Diseases |
| 10.2.2. Cattle Diseases |
| 10.2.2.1. FMD |
| 10.2.2.2. Infectious Respiratory Diseases |
| 10.2.2.3. Reproductive Disorders |
| 10.2.2.4. Others |
| 10.2.3. Companion Animal Diseases |
| 10.2.3.1. Rabies |
| 10.2.3.2. Hepatitis |
| 10.2.3.3. Leukemia |
| 10.2.3.4. Others |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. China |
| 10.3.2. India |
| 10.3.3. Japan |
| 10.3.4. ASEAN |
| 10.3.5. Australia & New Zealand |
| 10.3.6. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Country, 2023 - 2029 |
| 10.5. Asia-Pacific Swine, Ruminant and Companion Animals Vaccines Market Dynamics Trends |
| 11. Latin America Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Swine Vaccine |
| 11.1.1.1. Inactivated Vaccines |
| 11.1.1.2. Live Attenuated Vaccines |
| 11.1.1.3. Others |
| 11.1.2. Cattle Vaccine |
| 11.1.2.1. Toxoid |
| 11.1.2.2. Recombinant |
| 11.1.2.3. Inactivated |
| 11.1.3. Companion Animal Vaccines |
| 11.1.3.1. Attenuated Live Vaccine |
| 11.1.3.2. Inactivated Vaccine |
| 11.1.3.3. Others |
| 11.2. Disease Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Swine Diseases |
| 11.2.1.1. Diarrhea |
| 11.2.1.2. Swine Influenza |
| 11.2.1.3. Bordetella Rhinitis |
| 11.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 11.2.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 11.2.1.6. Other Diseases |
| 11.2.2. Cattle Diseases |
| 11.2.2.1. FMD |
| 11.2.2.2. Infectious Respiratory Diseases |
| 11.2.2.3. Reproductive Disorders |
| 11.2.2.4. Others |
| 11.2.3. Companion Animal Diseases |
| 11.2.3.1. Rabies |
| 11.2.3.2. Hepatitis |
| 11.2.3.3. Leukemia |
| 11.2.3.4. Others |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Rest of Latin America |
| 11.4. Latin America Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Country, 2023 - 2029 |
| 11.5. Latin America Swine, Ruminant and Companion Animals Vaccines Market Dynamics Trends |
| 12. Middle East and Africa Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 12.1. Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Swine Vaccine |
| 12.1.1.1. Inactivated Vaccines |
| 12.1.1.2. Live Attenuated Vaccines |
| 12.1.1.3. Others |
| 12.1.2. Cattle Vaccine |
| 12.1.2.1. Toxoid |
| 12.1.2.2. Recombinant |
| 12.1.2.3. Inactivated |
| 12.1.3. Companion Animal Vaccines |
| 12.1.3.1. Attenuated Live Vaccine |
| 12.1.3.2. Inactivated Vaccine |
| 12.1.3.3. Others |
| 12.2. Disease Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Swine Diseases |
| 12.2.1.1. Diarrhea |
| 12.2.1.2. Swine Influenza |
| 12.2.1.3. Bordetella Rhinitis |
| 12.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 12.2.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 12.2.1.6. Other Diseases |
| 12.2.2. Cattle Diseases |
| 12.2.2.1. FMD |
| 12.2.2.2. Infectious Respiratory Diseases |
| 12.2.2.3. Reproductive Disorders |
| 12.2.2.4. Others |
| 12.2.3. Companion Animal Diseases |
| 12.2.3.1. Rabies |
| 12.2.3.2. Hepatitis |
| 12.2.3.3. Leukemia |
| 12.2.3.4. Others |
| 12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Gulf Cooperation Council (GCC) Countries |
| 12.3.2. South Africa |
| 12.3.3. Rest of MEA |
| 12.4. MEA Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Country, 2023 - 2029 |
| 12.5. MEA Swine, Ruminant and Companion Animals Vaccines Market Dynamics Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Boehringer Ingelheim International GmbH. |
| 13.2.2. IDT Biologika GmbH |
| 13.2.3. HIPRA |
| 13.2.4. Ceva Sante Animale |
| 13.2.5. Elanco |
| 13.2.6. Arko Laboratories Ltd |
| 13.2.7. Merial |
| 13.2.8. Vetoquinol |
| 13.2.9. Zoetis Inc. |
| 13.2.10. Phibro Animal Health Corporation |
| 13.2.11. Merck & Co., Inc. |
| 13.2.12. Virbac |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
- Boehringer Ingelheim International GmbH.
- IDT Biologika GmbH
- HIPRA
- Ceva Sante Animale
- Elanco
- Arko Laboratories Ltd
- Merial
- Vetoquinol
- Zoetis Inc.
- Phibro Animal Health Corporation
- Merck & Co., Inc.
- Virbac